Replies to post #212040 on Biotech Values

[ciotera]

Re: Maviret

As expected.
But the press release for GILD's Vosevi includes the following:

The data included in the application support the use of SOF/VEL/VOX in patients with and without compensated cirrhosis, with all genotypes (GT1-6) of HCV infection regardless of prior therapy, including 8 weeks of treatment for HCV direct-acting antiviral (DAA)-naïve patients without cirrhosis, as well as 12 weeks of treatment for patients who have previously failed therapy with a DAA-containing regimen.


If naive non-cirrhotics end-up in the label for Vosevi (with 8 week duration) that is bad news for Maviret.